ValiRx chief says company is at an exciting phase as it updates on two key cancer candidates
Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders"
Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 2 of 4
Investments and investor services
FTSE 100 closes lower again as traders flee from risk
The UK blue chip index was about 10 points lower at 7,373, above the session low of 7,357.09 but below the morning peak of 7,397.74
Investments and investor services
Mosman the top riser in London after production update
Companies featured: Anglo Asian Mining, CloudCall, Greatland Gold, Mosman Oil & Gas, NCC, ValiRx
Archive
Proactive news snapshot: Mosman Oil And Gas, ValiRx, Anglo Asian Mining, Clinigen Group …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx advances as it wins patent protection pre-clinical drug to treat endometriosis
The gynaecological disorder occurs when tissue similar to the lining of the uterus, or endometrium, migrates outside of the womb, generally to the fallopian tubes, ovaries and tissue around the uterus
FTSE 100 closes higher as pound crashes amid Brexit worries
Footsie added nearly 26 points to stand at 7,626, while FTSE 250 also finished higher - up almost 71 points at 20,871
Valirx's talks in lung cancer highlight progress on all fronts
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.
EQTEC surges on new €22mln contract win
Some of the main news-driven risers and fallers in London on Thursday afternoon...
Archive
Proactive news snapshot: UK Oil & Gas Investments, ValiRx, Kazera Global …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx surges as it continues “advanced conversations” with possible partners for lung cancer drug
ValiRx released the positive results of a phase II trial of its lead drug earlier this year and it is now looking for a partner to help take VAL401 through a phase III study and into the market
ValiRx raises £0.95mln through a placing of 47.5mln new ordinary shares at 2.0p each
The firm said the funds will be used for progressing the clinical trial of VAL201 and for advancing the pre-clinical programmes, VAL101 and VAL301
Archive
Proactive news snapshot: ReNeuron Group, DP Poland, Minds + Machines …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Feedback, Futura Medical, Mosman Oil & Gas …
A glance at some of the day's highlights from the Proactive Investors newswire
Stellar Diamonds shares leap as court approves its acquisition by NWF
A look at some of the biggest risers and fallers in London on Wednesday
ValiRx receives EU patent grant for prostate cancer drug
The grant comes hot on the heels of a patent grant for the treatment in the US on 20 March
FTSE 100 pares losses as US bond yields rise above 3%
Resource stocks suffer as US dollar makes headway on forex markets
Archive
Proactive news snapshot: ValiRx, Stratex International, ANGLE …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
MyCelx ups full-year guidance as new order and equipment sale bring in US$2.7mln
MYCELX now expects full-year revenues to be in the range of US$16-17mln after the new order and equipment sale
ValiRx shoots higher, innovation effective at inducing programmed cell death in a wide range of cancers
The company is developing VAL101 in collaboration with academic and commercial partners in Finland, Germany and Denmark
FTSE 100 closes in the black as Shire surges; tobacco stocks drift lower
Shire shares ended 5.89% up as the group received and rejected a takeover approach from Japan's Takeda Pharma
Archive
Proactive news snapshot: Galileo Resources, ValiRx, ITM Power …
A glance at some of the day's highlights from the Proactive Investors newswire
D4t4 jumps as two ‘biggest ever contracts’ boost revenues and profits
The medical diagnostics group is planning on closing its sites in India and Germany as it looks to get back to profitability from a smaller revenue base
ValiRx chairman upbeat on the potential of two lead compounds
Last year saw the company make significant progress with VAL201 and VAL401
Archive
Proactive news snapshot: Amur Minerals, Strategic Minerals, Bloomsbury Publishing …
A glance at some of the day's highlights from the Proactive Investors newswire
LiDCO Group shares fall as it ends third party UK distribution agreement
A look at some of the biggest risers and fallers in London on Tuesday
ValiRx receives US patent protection for exciting lead cancer drug
The protection covers the molecule and a “wide variety of derivatives, modifications and analogues of the compounds and their mode of action”
Archive
Proactive news snapshot: Thor Mining, Papua Mining, Range Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Instem, Thor Mining, Anglo Asian Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Speculators keep GKN shares higher, FTSE 100 miners under fire
A look at some of the top risers and fallers in London today
ValiRx releases more positive data from VAL401 phase II lung cancer trial
The latest data from the trial shows that VAL401 had a positive impact on patients’ quality of life and doesn’t cause immune suppression like chemotherapy, for example
Investments and investor services
FTSE 100 closes lower as miners prove a drag
London’s blue-chip benchmark closed around 13 points lower on the day at 7,755
Archive
Proactive news snapshot: Lombard Risk Management, ValiRx, Connemara Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Boohoo shares edge lower as margins ease over Christmas trading period
A look at some of the top risers and fallers in London today
ValiRx given US patent boost for its lead therapeutic compound
VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours
FTSE 100 closes at third successive new high but retailers lag
FTSE 100 closed in London around 14 points higher at 7,762
ValiRx puts convertible loan note facility with Yorkville to bed
ValiRx confirms that there are no further obligations existing between itself and Yorkville
Westminster Group top London riser on Middle East opportunity update
Proactive takes a look at what's moving on a half day of London trading
Archive
Proactive news snapshot: Westminster Group, Motif Bio, Tavistock Investments, Valtrex …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx brings in £1mln from share sale which will be used to help fund trial of prostate cancer drug
The biotechnology company issued just over 23.5mln new shares
FTSE 100 reverses and closes in red as City packs up for Christmas
The Office for National Statistics (ONS) says that UK GDP grew by 1.7% in the three months to September
Archive
Proactive news snapshot: ValiRx, PowerHouse Energy, Chaarat Gold …
A glance at some of the day's highlights from the Proactive Investors newswire
One Media IP leaps as former BBC boss Michael Grade invests in the music rights holder
A look at some of the biggest risers and fallers on Monday in London
ValiRx given the green light to accelerate progress of prostate cancer drug after encouraging early results
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
FTSE 100 closes higher as US tax reform hopes cheer global traders
The UK blue chip index closed up 46.44 points at 7,537
Archive
Proactive news snapshot: ValiRx, W Resources, Falcon Oil & Gas …
A glance at some of the day's highlights from the Proactive Investors newswire
Surprise trading update is just the job for Robert Walters
The trading update was short and sweet. Liberum responded by increasing its target price.
ValiRx surges once again as top-line data from Phase II lung cancer trial impresses
ValiRx said its VAL401 anti-cancer compound had a “statistically significant” improvement in overall survival for patients with non-small cell lung cancer
FTSE 100 closes higher as energy stocks provide a boost; supermarkets weigh
Robert Walters sprang a pleasant surprise on the market with an unscheduled trading update.
ValiRx says YA II has converted second tranche of convertible loan facility at 1.25p per share
The life sciences company said YA II has elected to convert US$696,202.90 of its loan note, plus accrued interest of US$10,530, into 47,765,035 ordinary shares
ValiRx surges as it raises £1mln at a premium and confirms VAL401 phase II trial on track for readout this year
The £1mln will be used to advance the clinical trial of its lead compound, VAL201, as well as for advancing other pre-clinical programmes
Archive
Proactive news snapshot: Greatland Gold, SDX Energy, Asiamet Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Rurelec shares more than double as power plant operator confirms takeover talks
A look at some of the biggest risers and fallers today in London
ValiRx awarded fifth US patent for VAL401 cancer drug
“It is really pleasing to receive this notification of allowance for this latest VAL401 patent so close on the heels after our encouraging and positive announcement of first verified clinical data emerging from the VAL401 trial
FTSE 100 closes lower ahead of FOMC minutes
The FTSE 100 index closed down 4.46 at 7,533, below the session peak of 7,550.17 but above the low of 7,519.60
Petra Diamonds' shares sparkle after Tanzania lifts export ban
The government of Tanzania has given Petra the go-ahead to resume diamond exports and sales from the Williamson mine.
ValiRx opens higher as it completes dosing of VAL401 phase II cancer trial
Finial analyses from the study is expected by the end of the year
ValiRx praises “considerable progress” made in first half
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medi
Archive
Proactive news snapshot: Victoria Oil & Gas, Eco (Atlantic), Highlands Natural Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Nostra Terra doubles as it secures hedging facility with BP
"I am particularly pleased to confirm funds released through the hedging facility will not carry any geographical restrictions. This means we will be able to deploy capital across our entire portfolio," said CEO, Matt Lofgran
Archive
Proactive news snapshot: blur Group, PowerHouse Energy, accesso Technology…
A glance at some of the day's highlights from the Proactive Investors newswire
Swallowfield and Yü Group shares rise, while Metals Exploration languishes
Petro Matad was the morning's standout loser, with its shares losing more than 35%, meanwhile, in the blue-chip market the supermarkets were moving higher.
ValiRx raises £0.5mln via a placing of 50mln new ordinary shares at a price of 1p each
The AIM-listed biotechnology company said the funds raised will be used for “advancing the clinical dose escalation of VAL201 and for further progressing the late pre-clinical development of GeneICE and general working capital purposes”
Archive
Proactive news snapshot: Stratex International, Chariot Oil & Gas, ValiRx …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx to accelerate pre-clinical trials of cancer-fighting molecule after development breakthrough
The biotech has made a few tweaks to its VAL101 molecule which is now showing “much improved technical efficacy and commercially viable efficient manufacturing”
Some froth knocked off Mitchells & Butlers' shares after trading update boost yesterday
A glance at some of the bigger risers and fallers today in London ...
Cancer-focused ValiRx inks licensing agreement with Bangladeshi group Mystic Pharmaceuticals
Mystic Pharmaceuticals will get access to ValiRx's patented technology, including pre-clinical products
FTSE 100 fagged out as US Food and Drug Administration targets nicotine levels in cigarettes
Despite the beating meted out to IMPs and BATs, the Footsie rallied in the last half hour to trim its heavy losses
Archive
Proactive news round-up: Mariana Resources, Jubilee Platinum, Tethyan Resources ...
A glance at some of the stories on the Proactive newswire today
Defenx shares rise as it signs software distribution contract with BV-Tech
A look at the biggest risers and fallers in London today
ValiRx recruits three experienced industry figures to advisory board
Seppo Mäkinen, Dr Ajay Agrawal and Andrew King bring with them a wealth of industry and commercial experience
FTSE 100 closes lower as EU summit begins; oil weighs
The FTSE 100 dropped 8.5 to close at 7,439 on the day
Archive
Proactive end of day round-up: Jubilee Platinum, ANGLE, Seeing Machines...
A glance at some of the small cap stories on Proactive Investors today
Petro Matad rallies on Mongolian licence extension
Risers and fallers: DFS, Next, ANGLE boosted by Barts research, Starcom wins container order, Sprue Aegis delivers bullish AGM
ValiRx says patient recruitment for lung cancer study has been completed
VAL-401 is being developed jointly by ValiRx and Tangent Reprofiling as part of the pair’s ValiSeek collaboration.
FTSE 100 closes 55 down and UK mid-caps plunge; BoE raises prospect of rate rise
FTSE 100 closed down 55 at 7,419 as retail shares took a beating
ValIRx joint venture picks up patent in Australia for lung cancer compond
The drug is currently progressing through a Phase ll trial in Georgia with dosing to be completed by the end of 2017.
Investments and investor services
FTSE 100 closes higher as traders await Fed minutes
The FTSE 100 index closed up 29.61 at 7,514 with easyJet the biggest gainer
Archive
Proactive news round-up: Kibo Mining; DP Poland, Strategic Minerals...
A reverse takeover of Opera Investments is the method for the deal with the name of the company to be changed to Katoro Gold PLC to reflect the new business focus.
ValiRx happy with prostate and lung cancer drug trial progress
The AIM-listed group has two drugs currently in clinical trial: VAL201 for prostate cancer; and VAL401 for lung cancer.
Telit Communications shares slip after announcing £39mln cash call
Telit Communications shares have fallen after announcing a fundraising while Diversified Gas & Oil has gained on acquisition news
FTSE 100 rises as US non-farm payrolls report beats expectations
London's top tier index rose 22 points to 7,270.88 at 2.38pm after a better-than-expected US non-farm payrolls report
ValiRx offers low-risk, high return for investors, says analyst
ValiRx shares have gained today after Beaufort issued a 'speculative buy' rating and a target price of 6.0p
Restaurant Group back on menu on signs of stability
Some of the top rises and falls in London at 3.30pm: Restaurant Group, Inmarsat, Graphene Nanochem
ValiRx to publish mid-trial data from lung cancer study
A second clinic in Tbilisi, Georgia, has just started recruiting patients
Investments and investor services
FTSE 100 ended lower despite sterling weakness and Budget boost to builders
FTSE 100 shares ended down on Wednesday with sterling nursing a seven-week low despite a lift for construction stocks following the UK Finance Minister’s Budget pledge of a mini Trump boost to infrastructure
ValiRx raises £1.2mln to support clinical trial programmes
Certain directors of the company will be subscribing for £30,000 of shares at the same price as the share placing
ValiRx and Faron highlight different sides of pharma funding
Some the largest rises and fall at 3pm: ValiRx, Faron, Jersey Oil
ValiRx's cancer treatment recognised in peer-reviewed journals
ValiRx has been published in two journal articles for its work on developing drugs for cancer treatment
Archive
Webis sales rise not enough to offset margin concerns
Some the largest share price rises and fall in London at 3pm: Webis, Wey Education, ValiRx